Walleye Capital’s Inovio Pharmaceuticals INO Stock Holding History

Walleye Capital’s Portfolio INO Stock Details INO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-18,758	Closed	-$152K	–	5559
2024 Q2	$152K	Buy	+18,758	New	+$197K	﹤0.01%	4486

Other funds holding INO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Walleye Capital's INO Position: Q3 2024 in Review

Walleye Capital sold out of Inovio Pharmaceuticals (INO) in Q3 2024, closing a stake of 18,758 shares — an estimated $152K sold.

Walleye Capital first reported a position in INO in Q2 2024 and held it in 1 quarter. The position peaked at $152K in Q2 2024. 98 funds tracked by Wall St. Rank hold INO as of Q3 2024.

Walleye Capital reported no remaining Inovio Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
Walleye Capital sold 18,758 Inovio Pharmaceuticals shares in Q3 2024, an estimated $152K.
Walleye Capital first reported a position in Inovio Pharmaceuticals in Q2 2024 and held it in 1 quarter.
Walleye Capital's Inovio Pharmaceuticals position peaked at $152K in Q2 2024.
98 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q3 2024.

Based on Walleye Capital's 13F filing for Q3 2024, filed 14 Nov 2024.